Catalyst Pharmaceuticals, Inc.
(NASDAQ : CPRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
PTLAPortola Pharmaceuticals, Inc. 0.56%17.956.5%$165.07m
HZNPHorizon Therapeutics Plc 4.06%50.736.5%$146.36m
CTLTCatalent, Inc. 0.81%77.522.3%$138.66m
MYOKMyoKardia, Inc. 2.14%102.291.8%$130.35m
BHCBausch Health Cos., Inc. -0.75%18.440.0%$119.26m
VRXValeant Pharmaceuticals International, Inc. -0.75%18.4414.1%$108.50m
UTHRUnited Therapeutics Corp. 2.57%117.9514.3%$75.18m
JAZZJazz Pharmaceuticals Plc 0.45%119.322.4%$60.64m
ICPTIntercept Pharmaceuticals, Inc. -0.66%72.2616.8%$59.67m
AMRNAmarin Corp. Plc 0.44%6.861.6%$57.99m
GWPHGW Pharmaceuticals Plc -2.16%122.756.2%$55.98m
ARGXargenx SE 3.60%219.300.0%$52.90m
AXSMAxsome Therapeutics, Inc. 0.60%76.981.9%$50.67m
PRGOPerrigo Co. Plc -0.42%54.806.8%$45.78m
ICLRICON plc 1.72%168.454.3%$44.44m

Company Profile

Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.